Mylotarg (Gemtuzumab Ozogamicin)

Gemtuzumab ozogamicin, the active ingredient in Mylotarg, is an antibody‑drug conjugate presented as an intravenous formulation for use in adult patients with acute myeloid leukemia. It targets CD33‑positive leukemic cells and delivers a cytotoxic payload systemically to induce cell death.

GNH USA supplies Mylotarg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers benefit from reliable cold‑chain logistics and dedicated customer support throughout the procurement process.

Mylotarg is an antibody‑drug conjugate indicated for the treatment of acute myeloid leukemia, a malignant disease of the myeloid line. Acute Myeloid Leukemia (AML): improves remission rates and overall survival when used in combination with standard chemotherapy in adult patients. Relapsed or refractory AML: provides an additional therapeutic option for patients who have not responded to prior treatments. CD33‑positive AML: targets leukemic cells expressing the CD33 antigen, enhancing disease control.

Mylotarg may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate nausea reported during infusion. - Fatigue: transient tiredness experienced by many patients. - Fever: low‑grade fever occurring shortly after dosing. - Headache: occasional mild headache during treatment.

Serious or Rare Side Effects: - Veno‑occlusive disease (VOD): potentially life‑threatening liver injury. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Bleeding events: heightened risk of hemorrhage due to thrombocytopenia. - Severe allergic reactions: anaphylaxis or infusion‑related hypersensitivity requiring immediate medical attention.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor key clinical parameters. - Monitor liver function: assess transaminases and bilirubin before and during therapy. - Check blood counts: regular CBC to detect neutropenia and thrombocytopenia. - Assess for infection: watch for signs of febrile neutropenia. - Avoid in patients with known hypersensitivity to calicheamicin or any component. - Pregnancy: use only if potential benefit justifies potential risk, as safety is unknown. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mylotarg can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Hepatotoxic drugs (e.g., high‑dose acetaminophen): increase risk of liver injury.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may affect calicheamicin metabolism. - Warfarin or other anticoagulants: monitor coagulation parameters. - Live vaccines: avoid during treatment due to immunosuppression.